NEW YORK, July 17 - Intradigm will apply its small interfering RNA delivery technology to one of Europroteome's cancer targets, the companies said today.
Intradigm has developed a set of delivery systems for siRNA duplexes that can be delivered into pathological tissues, including human xenograft tumor models. The company said it has already used the technology to validate cancer targets.
Europroteome, meantime, has identified and validated its own cancer targets based on its proteomic and human-cell-based studies. The company said that using Intradigm's method to further validate these targets in tumor models "is expected to provide important information" related to its pre-clinical development program for its cancer targets.